CYT 503
Alternative Names: CYT-503; iPSCs-derived GPC3 CAR NK therapy - Cytovia Therapeutics/National Cancer InstituteLatest Information Update: 29 Apr 2022
At a glance
- Originator Cytovia Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer; Solid tumours
- Discontinued Ovarian cancer
Most Recent Events
- 27 Apr 2022 Cytovia Therapeutics plans phase I/II trials
- 18 Apr 2022 Discontinued for Ovarian cancer in USA (Parenteral) (Cytovia Therapeutics pipeline, April 2022)
- 18 Apr 2022 Preclinical trials in Liver cancer in USA (Parenteral) (Cytovia Therapeutics pipeline, April 2022)